Stanley Lapidus
Known title: DirectorCIK: 0001678195
Associated companies
Transaction History
| LUCD | ▲ Buy | Grant | 123,000 | $0 | 2/20/2026 | View on chart |
| LUCD | ▲ Buy | Grant | 112,800 | $0 | 2/20/2025 | View on chart |
| LUCD | ▼ Sell | Open Market | 10,000 | $15K | 9/26/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 10,000 | $14K | 9/26/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 9,747 | $14K | 9/26/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 200 | $286 | 9/25/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 100 | $144 | 9/21/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 3,405 | $5K | 9/20/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 412 | $593 | 9/20/2023 | View on chart |
| LUCD | ▼ Sell | Open Market | 17,000 | $29K | 9/20/2022 | View on chart |
| LUCD | ▼ Sell | Open Market | 16,864 | $29K | 9/20/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck
Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.
Lucid Diagnostics Expands Payment Pathways for EsoGuard and EsoCheck. Lucid Diagnostics announced it has advanced several payment, billing, and coding pathways for its EsoGuard® and EsoCheck® products. This development could streamline reimbursement for the company’s diagnostic tests, potentially improving cash flow and market acceptance. The update follows the firm’s recent efforts to broaden its product ecosystem. Analysts maintain a target of $4.00, while the stock trades near its 52‑week low.